Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.54 |
| ▸ | MDM4 | O15151 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 2/20 | 0.47 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TNF | P01375 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16801838 | 0.89 | SLC17A5 (0.55) | SLC17A5MDM4TP53TLR2CASP3 | |
| SCHEMBL4719374 | 0.88 | TLR2 (0.56) | SLC17A5MDM4TP53TLR2CASP3 | |
| SCHEMBL16801655 | 0.88 | SLC17A5 (0.54) | SLC17A5MDM4TP53HDAC1HDAC2 | |
| SCHEMBL27620508 | 0.87 | SLC17A5 (0.61) | SLC17A5MDM4TP53CASP3 | |
| SCHEMBL29401307 | 0.87 | SLC17A5 (0.61) | SLC17A5MDM4TP53CASP3 | |
| SCHEMBL29908094 | 0.87 | SLC17A5 (0.61) | SLC17A5MDM4TP53CASP3 | |
| SCHEMBL119188 | 0.87 | SLC17A5 (0.61) | SLC17A5MDM4TP53CASP3 | |
| SCHEMBL10073558 | 0.87 | TLR2 (0.59) | SLC17A5MDM4TP53TLR2CASP3 | |
| SCHEMBL8111105 | 0.87 | TLR2 (0.59) | SLC17A5MDM4TP53TLR2CASP3 | |
| SCHEMBL430008 | 0.86 | MDM2 (0.56) | MDM4TP53HDAC1HDAC2TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1551832-A1 | 8-AZABICYCLO[3.2.1]OCTANE ETHER DERIVATIVES AND THEIR USE AS NEUROKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2005-07-13 | — | — | EP | disclosed |
| EP-1504094-A2 | PEPTIDE COMPOUNDS AND THEIR USE AS PROTEASE SUBSTRATES | Pharmacia Corporation (US) | 2005-02-09 | — | — | EP | disclosed |
| WO-2004031185-A1 | 8-AZABICYCLO[3.2.1]OCTANE ETHER DERIVATIVES AND THEIR USE AS NEUROKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2004-04-15 | — | — | WO | disclosed |
| US-20040018561-A1 | Peptide compounds and their use as protease substrates | PHARMACIA CORPORATION | 2004-01-29 | — | — | US | disclosed |
| WO-2003095475-A2 | PEPTIDE COMPOUNDS AND THEIR USE AS PROTEASE SUBSTRATES | PHARMACIA CORPORATION (US) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040018561-A1 | Peptide compounds and their use as protease substrates | MMP3, MMP25, MMP11 | SLC17A5 493/4885MDM4 1345/4885TP53 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.